We are – right now – in the early stages of a massive new industry explosion.
In North America, the market for legal marijuana is soaring…showing unprecedented levels of sustained growth.
MYM Nutraceuticals, Inc. (OTC: MYMMF) (CSE: MYM) just recently signed a deal with the Government of Canada, in Quebec, to build the World’s largest, to date, Greenhouse Cannabis growing facilities (1.5 Million Sq. Feet).
Investors Should Watch Shares of MYM Nutraceuticals (OTC: MYMMF) (CSE: MYM) Closely in the Weeks and Months Ahead for Potentially Explosive Gains, unlike any other gains we have seen to date in this sector.
See the Press Release here: https://finance.yahoo.com/news/mym-nutraceuticals-build-one-worlds-125900805.html – As the street becomes more and more aware of MYM, you won’t likely see this PPS again.
As this overwhelming profit scenario unfolds, forward-thinking investors have the chance to tap into a once-in-a-generation opportunity.
The North American legal marijuana industry experienced growth of 30% — to $6.7 billion – in 2016…
And projections call for an annual growth rate of 25% through 2021 when the legal marijuana market is expected to top a whopping $20.2 billion.
According to Forbes, “ this industry growth is larger and faster than even the dot-com era.”
For investors, this early stage of a new industry’s growth is when fortunes are made.
But how do you separate the winning investments that could make you thousands of dollars from the losers that could drag down your portfolio?
After all, a handful of companies have already delivered triple-digit gains for early investors, including…
- Canopy Growth Corp. climbed 192% in 2016
- Medical Marijuana Inc. soared 281% in 2016
- Organigram Holdings soared 543% in 2016
- Axim Biotechnologies shot up 656% in 2016
- Aurora Cannabis skyrocketed 311% in 2016
- Supreme Pharmaceuticals climbed 583% in 2016
The key to finding explosive growth potential in fast-developing industries is to look for companies that offer three important things:
- A business model that allows for lightning-fast “scalability” and growth.
- A competitive advantage – or “moat” – that separates it from other companies.
- A leadership team with strong vision and a proven history of delivering successful growth.
One Canadian company right now stands alone as the single best way to play the red-hot legal marijuana market in North America because it possesses all three of these important traits.
Now You Can Profit from this 21st Century “Green Rush”
A major catalyst for the explosive growth in the North American marijuana market is coming from Canada.
On April 13, Canadian Prime Minister Justin Trudeau introduced legislation to legalize the recreational use of marijuana in Canada.
This legislation has triggered a massive race for market share among the country’s 43 licensed producers (LPs).
And because the Canadian government is working to push this legislation through quickly, Canada’s LPs are now scrambling to expand their capacity as quickly as possible…because they know that they’ll never again have this “post-prohibition” growth surge available to them.
But the large majority of Canada’s licensed producers are struggling with production.
Ramping up – and quickly – takes a huge commitment of manpower, resources and expertise…and many of these companies simply don’t have enough of any of them.
MYM Nutraceuticals is making acquisitions including completing its acquisition of 100 per cent of the brand and assets of HempMed, a Toronto-based developer and marketer of hemp-based cannabidiol (CBD) extracts and oil-infused nutraceutical products. This is a move we think brings significant value immediately.
The Critical Advantages of MYM Nutraceuticals Proven Business Model
On Testing and Standardization:
MYM has hired TheraCann Canada to implement its full suite of services including ISO 17025(2005) compliance to ensure repeatable and reliable data stands behind each product label. TheraCann is also providing TheraCannSYSTEM software to MYM, which directly captures all testing and analysis data to better control regulatory compliance concerns and future audits by Health Canada.
While Canada remains the base for MYM’s operations, the company has already begun expansion into the lucrative US market. In this case with CBD lines and hemp-based nutraceuticals.
Through its acquisition of HempMed, MYM has opened the door to distribute their CBD lines into the jurisdictions where the product is already accepted and legal under the medical guidelines. The current HempMed product line consists of over 20 Hemp products with plans to launch several more groundbreaking products over the next 12 months as a direct result of MYM’s involvement. MYM also plans on expanding HempMed’s existing distribution network, which consists of over 60 retail outlets and online sales portals across Canada, the USA, and Internationally.
The USA represents a huge and rapidly expanding market that MYM can tap by using HempMed as a strong entry point.
CANADA’S CANNABIS MARKET: PLENTY OF ROOM TO GROW
Based on legalization, the Marijuana market in Canada is projected to grow to CAD $22.8 Billion in just over two years. (Source: Deloitte)
SOLID COMPANIES WITH INTEGRATED OPERATIONS, DISTRIBUTION AND BRANDING WILL RISE TO THE TOP
Out of all the noise in this space the leaders will emerge. We’re convinced that the companies with integrated operations – from growing to cultivation, formula development to marketing and in distribution – will be able to leverage their position and take a significant lead in the race to market for cannabis. MYM Nutraceuticals is on the fast track.
The company has been building its brand and distribution, alongside its growth and product quality. They’ve combined this with experienced management and channel partners who can make them one of the leaders in this space.
We are looking for MYM and its comprehensive approach to start producing results immediately with a big upswing in revenue if the pathways to legal distribution are cleared.
“By 2026, investment firm Cowen & Co. anticipates total legal sales could reach $50 billion. In that case, the industry would experience more than 23% annual growth for a decade.”
We Give MYM Nutraceuticals Our “Strong Buy” Rating
MYM Nutraceuticals, Inc. provides investors the opportunity to get in early on a well-structured medical marijuana company with a professional business approach. Your investment is in MYM Nutraceuticals (OTC: MYMMF); (CSE: MYM), is in a public company with listing in the US via the OTC markets. This means that US investors can participate directly in a marijuana-based company, something not widely available in a US-based marijuana operation.
MYM is also a small cap stock with a market cap of just over $11M at present. This makes MYM’s stock very affordable compared to the large caps entering the space and could give investors incredible leverage.
The demand for cannabis, its derivatives and medicinal applications is increasing markedly, and early stage marijuana companies have seen consistent excellent growth as the sector gains momentum. We do not think this is simply a bubble.
MYM Nutraceuticals, currently around $.20 per share, could emerge as one of the big winners in the race to provide natural, premium quality cannabis and integrated solutions within this exploding industry.
Our recommendation: Our research says get in now on the ground floor. Take a significant position immediately and ride the wave of marijuana stocks with diversified interests. Look for key advances, news of agreements and acquisitions, along with signs that the legislation is increasing the target company’s stake in this potentially huge and rapidly expanding market worth billions.
Currently there are very few ways for US investors to invest in the rapidly developing marijuana industry due to current US Federal laws prohibiting US marijuana companies from going public.
MYM Nutraceuticals presents a truly unique opportunity: US investors can buy MYMMF shares on the US market since it is based in Canada. This enables US investors to invest directly into marijuana production and sales operations right now, and get in at the earliest point, instead of having to wait years for the Federal laws to change and letting the opportunities pass them by.
“This marijuana investment opportunity is just like investing in the Internet in 1997, there is no time to waste.”
//USA News Group
Disclaimer: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. usanewsgroup.com is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for MYM Nutraceuticals advertising and digital media. There may be other 3rd parties who may have shares in MYM, and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. The owner/operator of USA News Group has purchased a total of two thousand shares of MYM Nutraceuticals in the open market and own an additional five hundred and fifty five five hundred and fifty five thousand shares purchased through a subscription agreement (along with a corresponding amount of warrants exercisable at .40 starting October 3, 2017) and have no plans on selling these shares in the next 72 hours (from June 19, 2017) but reserve the right to buy and sell shares in MYM Nutraceuticals, Inc. at any point after June 22, 2017 – No further notice shall be given.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment